CRH completes latest phase in ongoing share buyback program

0Comments

CRH, a major building materials company, has completed the latest phase of its share buyback program. The company repurchased 2.2 million ordinary shares on the New York Stock Exchange between November 6, 2025 and February 17, 2026. This action returned an additional $0.3 billion to shareholders. Since the start of its share buyback initiative in May 2018, CRH has returned a total of $9.7 billion to shareholders.

The company also announced a new arrangement with Wells Fargo Securities, LLC to independently conduct another buyback program. Under this agreement, up to $0.3 billion worth of ordinary shares listed on the New York Stock Exchange may be repurchased on behalf of CRH. The new buyback will begin on February 19, 2026 and is set to conclude by April 28, 2026.

The maximum number of shares that may be acquired during this period is capped at 55 million. According to CRH, “The purpose of the Buyback is to reduce the share capital of CRH and the repurchased ordinary shares will be cancelled.” The company added that no purchases will take place outside the United States.

CRH stated that “The Buyback will be conducted within the parameters prescribed by the relevant buyback safe harbors under the U.S Securities Exchange Act and the UK Market Abuse Regulation (each as amended or supplemented).”

Decisions regarding future buybacks will depend on ongoing evaluations of business capital needs and market conditions.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.